We believe that clinical trials are necessary to establish secondary prevention measures related to attenuating the cardiovascular complications of T1D, even considering the use of other drugs that have demonstrated cardiovascular benefits in patients with T2D, such as SGLT2 inhibitors or GLP-1 analogues. Here, SLC5A2 is linked to type 1 diabetes mellitus.